Skip to main content

Table 1 Clinicopathological characteristic of LAR vs non-LAR patients in the FUSCC cohort

From: Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

Characteristic

Group

P value

LAR (n = 83)

non-LAR (n = 303)

Age (years)

  

  < 0.001

  ≤ 50

17 (20.5%)

146 (48.2%)

 

  > 50

66 (79.5%)

157 (51.8%)

 

Size (cm)

  

0.794

 ≤ 2

30 (36.1%)

111 (36.6%)

 

 > 2

53 (63.9%)

191 (63%)

 

 Unknown

0

1 (0.3%)

 

Menopause

  

0.004

 Yes

64 (77.1%)

175 (57.8%)

 

 No

19 (22.9%)

123 (40.6%)

 

 Unknown

0

5 (1.7%)

 

Grade

  

  < 0.001

 ≤ 2

28 (33.7%)

38 (12.5%)

 

 > 2

51 (61.4%)

230 (75.9%)

 

 Unknown

4 (4.8%)

35 (11.6%)

 

Ki67 (%)

  

  < 0.001

  < 30

30 (36.1%)

43 (14.2%)

 

  ≥ 30

46 (55.4%)

257 (84.8%)

 

 Unknown

7 (8.4%)

3 (1.0%)

 

LN status

  

0.008

 Positive

44 (53.0%)

108 (35.6%)

 

 Negative

38 (45.8%)

194 (64.0%)

 

 Unknown

1 (1.2%)

1 (0.3%)

 
  1. *Chi-square tests were used to analyze clinicopathological varibles, with patients of unknown information duly excluded